Oxaliplatina Mylan (Oxaliplatin)

Oxaliplatin is a platinum‑based chemotherapeutic that targets the DNA replication pathway in malignant cells.

• Colorectal cancer: used as part of the FOLFOX regimen to shrink tumour burden and improve survival.
• Gastric cancer: combined with other agents to enhance response rates.
• Pancreatic cancer: incorporated in multi‑drug protocols to increase tumour control.
• Ovarian cancer: used in selected regimens to achieve disease stabilization.
• Advanced solid tumours: employed in off‑label clinical trials to explore efficacy.

• Oxaliplatin forms reactive platinum‑DNA adducts that cause intra‑strand and inter‑strand cross‑links, disrupting DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing cancer cells while sparing most normal tissues.

Oxaliplatin may elicit a range of adverse reactions, from mild to severe, depending on patient factors and treatment context.

Common Side Effects

• Nausea and vomiting: frequent gastrointestinal upset during infusion.
• Peripheral neuropathy: tingling or numbness in the hands and feet, often dose‑related.
• Diarrhoea: loose stools that may require supportive care.
• Fatigue: generalized tiredness common during chemotherapy cycles.
• Thrombocytopenia: reduced platelet count increasing bleeding risk.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical intervention.
• Acute hemolytic anemia: rapid destruction of red blood cells.
• Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnoea.
• Cardiac arrhythmias: irregular heart rhythms observed during infusion.
• Neutropenic sepsis: life‑threatening infection due to low neutrophil counts.

When using Oxaliplatin, clinicians should assess patient history and monitor laboratory parameters throughout therapy.

• Renal function: adjust dosing or avoid use in severe impairment.
• Pre‑existing neuropathy: evaluate risk of worsening peripheral symptoms.
• Hepatic dysfunction: monitor liver enzymes and consider dose modification.
• Hematologic status: check complete blood counts before each cycle.
• Concomitant ototoxic drugs: avoid or closely monitor auditory function.
• Store at ambient temperature: keep in original packaging, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, altering efficacy or safety.

Major Interactions (Avoid)

• Aminoglycoside antibiotics: increased risk of nephrotoxicity.
• High‑dose vitamin C: may reduce platinum‑drug cytotoxicity.
• Live vaccines: immunosuppression can diminish vaccine effectiveness.

Moderate Interactions (Monitor Closely)

• Anticoagulants: heightened bleeding risk due to thrombocytopenia.
• NSAIDs: potential for additive gastrointestinal irritation.
• CYP‑mediated drugs: minor alterations in drug metabolism observed.